Zogenix selling $60m in stock to finance Zohydro
This article was originally published in Scrip
Executive Summary
Zogenix said it will sell $60m worth of common stock in an underwritten public offering primarily to finance pre-commercial activities and commercialization for the pain drug Zohydro ER (hydrocodone bitartrate), which in late October became the first extended-release formulation of hydrocodone and acetaminophen approved by the US FDA (scripintelligence.com, 26 October 2013).